中文(简体)
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Prebiotic Effects of Isomalto-oligosaccharide

只有注册用户可以翻译文章
登陆注册
链接已保存到剪贴板
状态已完成
赞助商
George Mason University

关键词

抽象

The primary purpose of this study is to evaluate the effect of an IMO nutritional supplement on gut microbiome, gut health, and body weight. Two formulations of the supplement will be evaluated; thus, there will be three study arms: Supplement A, Supplement B, and placebo. Stool samples will be analyzed for bacterial DNA. The gut bacterial DNA, body weight, and gut health data will be compared across supplement and placebo groups.
Primary Aim 1: To evaluate the effect of the IMO supplement on gut bacterial abundance, diversity, and gene function across intervention and placebo groups, and across two doses of the intervention.
Secondary Aim 1: To evaluate the effect of the IMO supplement on gut health across intervention and placebo groups, and across two doses of the intervention.
Secondary Aim 2: To evaluate the effect of the IMO supplement on body weight across intervention and placebo groups, and across two doses of the intervention.
60 subjects, randomized to three arms (20 each: Supplement formula A, Supplement formula B or placebo) will take a daily dose of Supplement A, Supplement B, or placebo for 8 weeks. The supplement is a light syrup liquid. Ingredients that are in the supplement are: isomalto-oligosaccharide, water, mannitol, maltose, glucose, and glycerol. Ingredients that are in the placebo are: high maltose corn syrup (Satin Sweet™), water, and mannitol. Dose will be 500 mg during the first 4 weeks and then 1000 mg for second 4 weeks. Subjects will be instructed to take 500 mg/day of the supplement or placebo the first four weeks and 1000 mg/day of the supplement or placebo for the second four weeks. Subjects will be blinded as to whether they are receiving placebo or supplement. After screening and once enrolled, subject involvement includes visits to George Mason University, being weighed, dropping off stool samples, and completing a survey on gut health. Stool samples will be analyzed for bacterial DNA. The gut bacterial DNA, weight, and gut health data will be compared across supplement and placebo groups.

日期

最后验证: 02/28/2017
首次提交: 04/24/2015
提交的预估入学人数: 05/03/2015
首次发布: 05/04/2015
上次提交的更新: 03/20/2017
最近更新发布: 03/22/2017
实际学习开始日期: 03/31/2015
预计主要完成日期: 10/31/2015
预计完成日期: 11/30/2016

状况或疾病

Microbiota

干预/治疗

Dietary Supplement: Isomalto-oligosaccharide

-

手臂组

干预/治疗
Placebo Comparator: Placebo
Ingredients that are in the placebo are: high maltose corn syrup (Satin Sweet™), water, and mannitol. Both Supplement A and Supplement B will be compared to this placebo arm.
Experimental: Supplement A
Ingredients that are in the supplement are: isomalto-oligosaccharide, water, mannitol, maltose, glucose, and glycerol. Supplement A and B differ by degrees of polymerization.
Experimental: Supplement B
Ingredients that are in the supplement are: isomalto-oligosaccharide, water, mannitol, maltose, glucose, and glycerol. Supplement A and B differ by degrees of polymerization.

资格标准

有资格学习的年龄 18 Years 至 18 Years
有资格学习的性别All
接受健康志愿者
标准

Inclusion Criteria:

- Provide signed and dated informed consent form

- Willing to comply with all study procedures and be available for the duration of the study

- Male or female, aged 18 to 45 years of age

- In good general health as evidenced by medical history

- Women of reproductive potential must use highly effective contraception

- Body mass index of 25 kg/m2 or higher

- Weigh less than 350 lbs.

Exclusion Criteria:

- History of colon cancer

- History of rheumatoid arthritis

- Active self-reported febrile illness (may enroll after 2-week waiting period following the day that the illness/fever is resolved)

- Taking TNF-alpha inhibitors, COX2 inhibitors, JAK inhibitors

- History of hypothyroidism (with or without treatment)

- History of inflammatory bowel disease (ulcerative colitis and Crohn's disease)

- Type I or Type II diabetes

- History of Parkinson's Disease, Huntington's Disease or Multiple Sclerosis

- History of major depression, bipolar disorder, or schizophrenia

- Pregnant or lactating women

- Currently suffering from migraine headaches (at least one migraine headache in the past 30 days)

- Current use of any prescription or non-prescription weight loss products

- Consumption of more than 2 drinks per day of alcohol

- Tobacco smoker (over ½ pack per week is excluded)

- Marijuana smoker (over once per month is excluded)

- Currently have an eating disorder including anorexia nervosa, bulimia, and/or obsessive compulsive disorders

- Plan to start a new diet or make changes to their current diet during the study

- Diagnosis of Coronary Artery Disease who have had chest pain within the past 2 months

- Diagnosis of Congestive Heart Failure who have had any episodes of shortness of breath within the last 2 months

- History of stroke within the past 1 year

- History of ventricular tachycardia or fibrillation

- History of hypertension that has been difficult to control with medication (based on medical history - e.g. requiring more than 2 medication to achieve control)

- History of seizures in the last 5 years

- Cancer diagnosis in the last 5 years (except non-melanoma skin cancer or in-situ cervical cancer)

- History of bariatric or lapband surgery

- Usual or planned consumption of more than 2 servings per week of yogurt, kombucha, kefir, or kimichi

- Regular use of antibiotics

- Use of antibiotics in the previous 2 weeks

- Current and continued use of prebiotics or probiotics

- Known allergic reactions to components of the study supplement or placebo

结果

主要结果指标

1. Change in gut bacterial DNA from baseline, extracted from fecal sample [4 weeks]

2. Change in gut bacterial DNA from baseline, extracted from fecal sample [8 Weeks]

次要成果指标

1. Body weight change from baseline [Week 4]

2. Change from baseline in self-reported digestive health measured by questionnaire [Week 4]

3. Change from baseline in self-reported digestive health measured by questionnaire [Week 8]

4. Body weight change from baseline [Week 8]

加入我们的脸书专页

科学支持的最完整的草药数据库

  • 支持55种语言
  • 科学支持的草药疗法
  • 通过图像识别草药
  • 交互式GPS地图-在位置标记草药(即将推出)
  • 阅读与您的搜索相关的科学出版物
  • 通过药效搜索药草
  • 组织您的兴趣并及时了解新闻研究,临床试验和专利

输入症状或疾病,并阅读可能有用的草药,输入草药并查看所使用的疾病和症状。
*所有信息均基于已发表的科学研究

Google Play badgeApp Store badge